Symfi (efavirenz/lamivudine/tenofovir disoproxil fumarate) / Viatris - LARVOL DELTA

Incidence of antiretroviral therapy regimen modification and associated factors among People Living with HIV in Beijing, China. (PubMed, PLOS Glob Public Health) - "TDF + 3TC + EFV was the predominant initially prescribed regimen with the highest durability, while LPV/r + 3TC + AZT had the highest modification rate. These findings underscore the need for early ART initiation, comprehensive pretreatment screening, and enhanced early monitoring-especially during the first six months-to optimize regimen selection and minimize unnecessary modification."

Journal • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Efficacy, and safety of ainuovirine-based antiretroviral regimen in women with HIV-1: the pooled analysis of the RACER, and SPRINT studies, two multicenter, randomized, active controlled phase 3 trials (EACS 2025) - "Method : In the RACER study (N=34), 18, and 16 treatment-naïve WWH were medicated with ANV/3TC/TDF, and EFV/3TC/TDF, respectively. In the SPRINT study (N=22), 11, and 11 virologically suppressed WWH were medicated with ANV/3TC/TDF, and E/C/F/TAF, respectively...Conclusions : At a small sample size, ANV/3TC/TDF regimen showed high viral suppression comparable to the comparators in women. Accompanied benefits included less neuropsychiatric symptoms for treatment-naïve women, and improved lipid metabolism for both subpopulations."

P3 data • Retrospective data • Human Immunodeficiency Virus • Infectious Disease • CD4

Efficacy, and safety of ainuovirine plus lamivudine, and tenofovir DF in young people with HIV-1: pooled analyses of RACER, and SPRINT studies, two randomized, active-controlled phase 3 trials (EACS 2025) - "This study evaluated ainuovirine (ANV), a next-generation NNRTI with demonstrated non-inferior efficacy to efavirenz (EFV) and elvitegravir/cobicistat (E/C) in phase 3 trials, focusing on young people with HIV-1 (YPWH) across treatment-naïve (TN), and virologically suppressed (VS) populations. Method : We pooled data from two randomized trials: RACER (TN, N=219; ANV/3TC/TDF vs EFV/3TC/TDF) and SPRINT (VS, N=107; ANV/3TC/TDF vs E/C/F/TAF)...The combination of maintained viral suppression, improved CD4 cell recovery, attenuated weight gain, better lipid control, and preserved renal function positions ANV/3TC/TDF as an optimized treatment option for YPWH, particularly in Asia-Pacific regions where metabolic complications are of growing concern. These findings support ANV's role as a valuable alternative to the antiretroviral armamentarium for this vulnerable population."

Clinical • P3 data • Human Immunodeficiency Virus • Infectious Disease • CD4

Machine Learning Algorithms for Adverse Drug Reactions Prediction and Identifying Its Determinants Among HIV Patients on Antiretroviral Therapy in the University of Gondar Comprehensive and Specialized Hospital, in Amhara Region, Ethiopia. (PubMed, Health Sci Rep) - "The top eight predictors of ADRs were identified by random forest feature importance and association rules as follows: Male, younger age, longer duration on ART, not taking Co-trimoxazole preventive therapy (CPT), not taking TB (Tuberculosis) preventive therapy (TPT), secondary educational status, TDF-3TC-EFV, and low CD4 counts. Our research shows that HIV patients who are at a high risk of adverse drug reactions and those who can recognize the predictive traits associated with the ADRs can be categorized according to how effectively their ART treatment is working. However, our research may help address the pressing public health issue of diagnosing and treating HIV-positive individuals."

Adverse drug reaction • Journal • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CD4

Patterns of Reverse Transcriptase Inhibitor Resistance Mutations in People Living with Human Immunodeficiency Virus in Libreville, Gabon. (PubMed, Trop Med Infect Dis) - "Three of the most prescribed treatment regimens were associated to the appearance of both NRTIs and NNRTIs resistance mutations: TDF + 3TC + EFV (24.02%; 160/666); TDF + FTC + EFV) (17.2%; 114/666) and AZT + 3TC + EFV (14.6%; 97/666)...Also, treatment containing TDF-3TC + DTG is more protective against mutations. Drug resistance mutations are common in Gabon and compromise the efficacy of ART. Further study must search for other causes of therapeutic failure in Gabon in PWHIV."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4

Current status of antiretroviral treatment for people living with human immunodeficiency virus in Burkina Faso in the era of the World Health Organization's "test and treat" strategy (PubMed, Med Trop Sante Int) - "The main treatment combination used in adults was TDF/FTC/EFV, accounting for 42% in 2018, 50% in 2019, and 38% in 2020. The TDF/3TC/EFV combination was dominant in 2021, accounting for 46%. In 2022 and 2023, the TDF/3TC/DTG combination was the most common, at 76% in 2022 and 91% in 2023...The proportion of people on ART has gradually increased since the WHO's "test and treat" recommendations. These results bring Burkina Faso closer to achieving the UNAIDS targets."

Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Efficacy, and safety of ainuovirine-based antiretroviral regimen in women with HIV-1: the pooled analysis of the RACER, and SPRINT studies, two multicenter, randomized, active controlled phase 3 trials (IAS-HIV 2025) - "This integrated analysis aimed to evaluate the virological outcomes, and safety profile of ANV/3TC/TDF in women with HIV-1 (WWH) at week 48. In the RACER study (N=34), 18, and 16 treatment-naïve WWH were randomized, and medicated with ANV/3TC/TDF, and EFV/3TC/TDF, respectively. In the SPRINT study (N=22), 11, and 11 virologically suppressed WWH were randomized, and medicated with ANV/3TC/TDF, and E/C/F/TAF, respectively... Although at a small sample size, ANV/3TC/TDF regimen showed high viral suppression comparable to the comparators in both treatment-naïve, and virologically suppressed women."

P3 data • Retrospective data • Human Immunodeficiency Virus • Infectious Disease • CD4

Metabolic Health Consequences of Switching to the Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir Plus Lamivudine Regimens in Virologically Suppressed People Living with HIV Aged > 40 Years: A Retrospective Real-World Study. (PubMed, Infect Drug Resist) - "This study aimed to evaluate the safety and metabolic health consequences of two switched regimens in a real-world setting among virologically suppressed PLWH previously treated with EFV/TDF/3TC. In this study, the B/F/TAF or DTG/3TC regimens are safe for virologically suppressed PLWH aged > 40 years. The transition to B/F/TAF demonstrated dual clinical benefits, significantly reducing hyperglycemia incidence while preserving renal function."

Journal • Real-world evidence • Retrospective data • Diabetes • Human Immunodeficiency Virus • Infectious Disease

The cost-effectiveness analysis of single-tablet efavirenz-based regimen among HIV-1 infected adults in China. (PubMed, Front Public Health) - "In 2018, the Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS recommended the adoption of the efavirenz 400 mg-based TLE (tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + efavirenz (EFV)) regimen as the primary first-line treatment for ART-naive HIV-1 infected adults in China. In probabilistic sensitivity analysis, TLE400 STR demonstrated a 71.4% probability of being highly cost-effective nationwide, based on the one-time national-level GDP per capita. In the context of treating HIV-1 infected adults in China, the STR of TLE400 demonstrated cost-effectiveness when compared to both the MTR of TLE400 and the MTR of TLE600."

HEOR • Journal • Human Immunodeficiency Virus • Infectious Disease

INSTIs-centered antiviral regimens for first-line treatment of HIV/AIDS: a network meta-analysis and cost-effectiveness analysis. (PubMed, BMC Infect Dis) - "INSTI-based regimens are as effective and safe as the national standard but offer additional benefits in drug resistance and patient compliance. B/F/TAF is economically viable from the patient perspective but does not present a cost-utility advantage from the healthcare system perspective. This study underscores the need for considering both clinical and economic factors in selecting first-line HIV/AIDS treatments in China."

Clinical • HEOR • Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease • CD4

Transitioning Adolescents With HIV to TDF/3TC+DTG Improves Virologic Outcome: CIPHER-ADOLA Study (CROI 2025) - "Background WHO recommends transitioning to tenofovir/lamivudine/dolutegravir (TLD)-regimen to improve virological success (VS), considering vulnerable populations like adolescents living with HIV/AIDS (ADLHIV). However, VR occurs in some cases, especially when switching from a DTG-based regimens. Thus, scaling-up the transition of ADLHIV to TLD, regardless of previous exposure to TDF/3TC/EFV and baseline VL, would contribute to markedly decreasing, down toward eliminating paediatric AIDS."

Human Immunodeficiency Virus • Infectious Disease • Pediatrics

Efficacy and safety of an Albuvirtide-based regimen for preventing mother-to-child transmission of multidrug-resistant HIV: a case report. (PubMed, BMC Pregnancy Childbirth) - "In our case, ABT-based antiretroviral regimen was effective in suppressing viral load (VL) in pregnancy, and there is no reported safety issues for the mother or the baby. Albuvirtide use in pregnancy might represent a strategy to avoid in utero transmission of MDR-HIV, but further investigation is warranted."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4

Impact of different antiretroviral therapy regimens on bone mineral density in people living with HIV: a retrospective and longitudinal study in China. (PubMed, BMC Infect Dis) - "TAF-containing and DTG-containing regimens caused less bone loss than TDF + 3TC + EFV, offering safer options for preserving bone health in Chinese PLWH."

Journal • Observational data • Retrospective data • Human Immunodeficiency Virus • Infectious Disease • Osteoporosis

Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with HIV‐1 (PWH): a systematic literature review (SLR) of clinical and patient‐reported outcomes (PROs) (HIV-Glasgow 2024) - "Efficacy and safety outcomes at key timepoints reported by included rapid start (RS) studies Characteristic/Endpoints BIC-NOW (Spain) [5] BIFAST (Spain) [6] FAST (France) [7] Rainbow (Italy) [8] Test&Treat (Spain) [9] Benidir 2022 (USA) [10] Study design Single arm Single arm Single arm Single arm Single arm Non-RCT (RS vs non-RS) Phase IV IV IV IV III NR Treatment arms B/F/TAF RS (n=208) B/F/TAF RS (n=59) B/F/TAF RS (n=112) B/F/TAF RS (n=30) B/F/TAF RS (n=100) B/F/TAF RS (n=65) B/F/TAF non-RS (n=42) Efficacy Outcomes Virologic suppression (Viral load <50 copies/mL) W24 (n=160), 88.8% W24 (n=59), 84.4% W24 (n=112), 80.4% W24 (n=30), 80%, p < 0.001 W4 (n=100), 52% Visit 5 (timepoint NR) (n=65), 100%, p ≥ 0.05 Visit 5 (timepoint NR) (n=42), 100% Engagement in care (Attendance at visits) W48 (n=30), 100% W4 (n=100), 100% Visit 4 (median 192.0 [IQR 185.0,238.0] days) (n = 16), 56.3%, p = 0.003 Visit 4 (median 243.5 [IQR 180.2, 306.8] days) (n = 22), 9.1% Safety..."

Clinical • Patient reported outcomes • Review • CNS Disorders • Depression • Human Immunodeficiency Virus • Infectious Disease • Mood Disorders • Psychiatry

BIC/FTC/TAF Benefits People Living With HIV After Omicron Breakthrough Infection in Shortening Duration of Symptoms, Enhancing Specific Immune Response and Increasing Total CD4 Cells. (PubMed, J Med Virol) - "In cellular immunity, the use of BIC/FTC/TAF was also found to increase not only BA.5-specific B lymphocytes and BA.5-specific CD4+T lymphocytes, but also total CD4+T cells. In conclusion, compared to TDF/3TC/EFV, BIC/FTC/TAF can help PLWH shorten the duration of COVID-19 symptoms, enhance SARS-CoV-2 specific humoral and cellular immune responses, help to expand the total CD4+T cells increase in PLWH after Omicron infection and may be more beneficial for PLWH with high risk of infection in the context of COVID-19 normalization."

Journal • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4

High virological suppression in treatment‐naïve people with HIV‐1 on ainuovirine‐ versus efavirenz‐ based antiretroviral regimen as initial therapy: effect of pretreatment NNRTI resistance from RACER trial, a multi‐centre, randomized, active‐controlled study (HIV-Glasgow 2024) - "Virological outcomes of treatment-naïve people with HIV-1 on ANV- versus EFV-based antiretroviral regimen as initial therapy at week 48 (PDR to NNRTI subgroup, N = 71) n (%) ANV+3TC+TDF (N = 44) EFV+3TC+TDF (n = 27) Viral suppression (HIV RNA <50 copies/ml) 36 (81.8) 18 (66.7) Incomplete viral suppression (observed HIV RNA ≥50 copies/ml) 3 (6.8) 4 (14.8) HIV RNA ≥50∼<1000 copies/ml 2 (4.5) 3 (11.1) HIV RNA ≥1000 copies/ml 1 (2.3) 1 (3.7) No virological data 5 (11.4) 5 (18.5) Abbreviations: 3TC, lamivudine; ANV, ainuovirine; EFV, efavirenz; NNRTI, non-nucleoside reverse transcriptase inhibitor; PDR, pretreatment drug resistance; RNA, ribonucleic acid; TDF, tenofovir disoproxil fumarate. ANV-based antiretroviral regimen achieved a relatively high VS in treatment-naïve PWH although PDR to NNRTI prevailed in the study population. In consideration of additional safety benefits of ANV compared to EFV, ANV-based regimen is recommended as a first-line treatment..."

Clinical • Human Immunodeficiency Virus • Infectious Disease

Good-first: B/F/TAF As First-line ART (clinicaltrials.gov) - P=N/A | N=630 | Recruiting | Sponsor: Affiliated Hospital of Nantong University

New trial • Human Immunodeficiency Virus • Infectious Disease • CD4

Association of first-line combination antiretroviral therapy with malaria among adult HIV-infected persons in Jos, Nigeria: a pilot cross sectional study. (PubMed, BMC Infect Dis) - "Malaria parasite burden in HIV-infected persons on first-line cART is lower than that observed in ARV-naïve HIV-infected persons. Our study suggests that TDF/3TC/EFV may be associated with lower malaria antigenaemia when compared with AZT/3TC/NVP and can be considered an alternative first-line antiretroviral regimen in malaria-endemic regions."

Journal • Observational data • Human Immunodeficiency Virus • Infectious Disease • Malaria • Pain

The risk of dyslipidemia on PLHIV associated with different antiretroviral regimens in Huzhou. (PubMed, PLoS One) - "The prevalence of dyslipidemia varies according to different antiretroviral regimens. Using both horizontal and longitudinal data, we have repeatedly demonstrated that AZT has a more adverse effect on blood lipids than TDF from two perspectives. Therefore, we recommend caution in using the 3TC+EFV+AZT regimen for people at clinical risk of co-occurring cardiovascular disease."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders

Human leukocyte antigen HLA-B*57:01 status in HIV-1 patients developing hypersensitivity reactions in Benin: a pilot study. (PubMed, BMC Res Notes) - "Our study revealed that HLA-B*57:01 allele was very rare in PLHIV-1 in Benin, suggesting that its screening before starting the Abacavir regimen did not seem necessary."

Journal • Human Immunodeficiency Virus • Immunology • Infectious Disease • CD4 • HLA-B

Viral suppression and drug resistance patterns among MSM in Cameroon: evidence supporting elimination of HIV in key populations (AIDS 2024) - "Regarding ART history, median [IQR] duration on ART was 4 [2-5] years and most prescribed ART regimens were TDF+3TC+DTG (95%; 78/82); TDF+3TC+EFV (2.4%; 2/82) and ATV/r+3TC+TDF (2.4%; 2/82). Among ART-experienced MSM in Yaoundé, receiving predominantly DTG-containing regimens, viral suppression rate is above the 95% target, indicating prevention of HIV transmission among this KP. Furthermore, the low rate of HIVDR underscores the high effectiveness of current ART regimens used among KP in similar LMICs."

Clinical • Human Immunodeficiency Virus • Infectious Disease

Factors associated with an above average decline in estimated glomerular filtration rate following substitution with DTG among people living with HIV in Eswatini (AIDS 2024) - "BACKGROUND: Dolutegravir is known to result in a physiologic decrease in estimated glomerular filtration rate (eGFR) of 16-19mL/min/1.73m2 due to inhibition of tubular creatinine secretion. This analysis evaluated adults in Eswatini transitioning from TDF/3TC/EFV (TLE) to TDF/3TC/DTG (TLD) to determine whether observed reduction in eGFR is aligned with published literature and to identify risk factors for eGFR reductions of greater than 20%. This is a retrospective observational cohort study of electronic medical record data at Baylor College of Medicine Children's Foundation-Eswatini among adults living with HIV who were on TLE prior to a transition to TLD... After switching to TLD, the mean change in eGFR observed in Eswatini aligns with published reports. This post-marketing data is reassuring and confirms observations from clinical trials. Identifying risk factors for a greater than expected change in eGFR can help clinicians to better monitor those who might be..."

Chronic Kidney Disease • Genetic Disorders • Human Immunodeficiency Virus • Infectious Disease • Obesity

Unraveling the nexus: the impact of depression on virological outcomes among people with HIV in South Africa (AIDS 2024) - "The study involved 98 cases ( > 1000 copies/mL) and 199 controls (< 1000 copies/mL) in a 1:2 ratio matched for age, gender, study site, and duration of ART ([EFV/TDF/3TC]).Both groups participated in a follow-up interview conducted by a blinded research assistant and included a structured questionnaire and the Kessler 10 (K-10) depression scale... This research underscores the interplay among depression, medication adherence, and VF previously understudied in this population. These findings offer insights for the development of holistic care approaches tailored to the HIV-affected population in South Africa. Emphasis on policies incorporating mental health strategies into the broader framework of the HIV care continuum to enhance overall treatment effectiveness and well-being is essential for continued success for the 95-95-95 goals."

CNS Disorders • Depression • Human Immunodeficiency Virus • Infectious Disease • Major Depressive Disorder • Mood Disorders • Psychiatry

Acquired drug resistance to dolutegravir among people living with HIV in Cameroon: implications on treatment strategies in low- and middle-income countries (AIDS 2024) - "BACKGROUND: The World Health Organisation (WHO) recommends dolutegravir (DTG)-based regimens as the preferred antiretroviral therapy (ART) in low- and middle-income countries (LMICs). Though transition to TLD is generally successful, InSTI-resistance emergence is detected in cases following transition on first-line therapy to TLD with unsuppressed-viremia; switching to third-line regimen without the benefit of genotypic resistance data (functional-monotherapy); or co-administration of DTG and anti-TB drugs. Considering these case-scenarios for public-health actions in the landscape of treatment strategies, would substantially limit the emergence of resistance to DTG in LMICs."

Human Immunodeficiency Virus • Infectious Disease • Respiratory Diseases • Tuberculosis • CD4

Strengthening enhanced adherence counselling to people living with HIV with a high viral load and suppression in Northern Cameroon (AIDS 2024) - "TDF 3TC DTG was the most common protocol in this group (76.6%) and secondly TDF 3TC EFV (14.5%). The results of this work reinforce the need to adhere to guidelines for managing high viral loads. PLHIV with very high VL are the most at risk of non-suppression despite counseling sessions. More attention should be paid to this group."

Adherence • Human Immunodeficiency Virus • Infectious Disease